Search
PXT 3003
go.drugbank.com/drugs/DB16745InvestigationalPXT 3003 is in phase 3 clinical trials for the treatment of Charcot-Marie-Tooth disease type 1A in adults.
SIS-101-ADO
go.drugbank.com/drugs/DB18085ExperimentalSIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).[L48091]
Mecapegfilgrastim
go.drugbank.com/drugs/DB19147InvestigationalMecapegfilgrastim is under investigation in clinical trial NCT05463601 (Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer).
Amrubicin
go.drugbank.com/drugs/DB06263InvestigationalIn 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006.
Varespladib
go.drugbank.com/drugs/DB11909InvestigationalVarespladib has been investigated for the treatment and prevention of Sickle Cell Disease, Vaso-occlusive Crisis, and Acute Coronary Syndrome.
Adenosine-5'-Monophosphate Glucopyranosyl-Monophosphate Ester
go.drugbank.com/drugs/DB01774ExperimentalServes as the glycosyl donor for formation of bacterial glycogen, amylose in green algae, and amylopectin in higher plants. [PubChem]
Glycocholic acid
go.drugbank.com/drugs/DB02691InvestigationalIt acts as a detergent to solubilize fats for absorption and is itself absorbed.
Mibolerone
go.drugbank.com/drugs/DB11429ExperimentalVet approvedMibolerone is a potent anabolic steroid which is both higher affinity and more selective for the androgen receptor than metribolone.
Lenomorelin
go.drugbank.com/drugs/DB11895InvestigationalLenomorelin has been investigated for the treatment and basic science of Cancer, Alcoholism, Metabolism, Hypopituitarism, and Frailty Syndrome, among others.
Indium In-111
go.drugbank.com/drugs/DB11916InvestigationalIndium In-111 is under investigation in clinical trial NCT00493454 (Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas).